Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. CytoDyn's annualizedGross Profit for the quarter that ended in Feb. 2024 was $0.00 Mil.
CytoDyn's average Total Assets over the quarter that ended in Feb. 2024 was $9.76 Mil. Therefore, CytoDyn's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2024 was 0.00%.
CytoDyn Gross-Profit-to-Asset % Historical Data
The historical data trend for CytoDyn's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoDyn's Gross-Profit-to-Asset %
For the Biotechnology subindustry, CytoDyn's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where CytoDyn's Gross-Profit-to-Asset % falls into.
CytoDyn Gross-Profit-to-Asset % Calculation
CytoDyn's annualized Gross-Profit-to-Asset % for the fiscal year that ended in May. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Feb. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
CytoDyn Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of CytoDyn's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYDY has been successfully added to your 